The specter of generic rivalry has repeatedly loomed around copyright’s blockbuster drug, Viagra, triggering questions about the outlook of similar drug investments. While first years saw substantial returns, the intellectual property lapse has created the way for less expensive copies, possibly lowering earnings and presenting a significant risk